• What do your urinary symptoms mean?

    Suffering from urinary symptoms? It may be an enlarged prostate.

    Learn more about an enlarged prostate, also known as BPH,1 how it affects you, and what causes it. Exploring your own symptoms and measuring them are the first steps toward relief.

  • What makes RAPAFLO® the right choice for you?

    Your symptoms can be disruptive. Get rapid and continued relief.2,3

    Learn how RAPAFLO® targets and relaxes the prostate to quickly relieve symptoms of an enlarged prostate. Explore why it works, and its side effects to determine if RAPAFLO® is right for you.

  • How can you stay on track if you’re already taking RAPAFLO®?

    You’ve made the right decision to take control. Now, stick with it.

    Learn how RAPAFLO® works fast and then keeps working to improve your symptoms over time.2,3 Check your improvement by using the Symptom Calculator again.

 
 
 
 
  • REFERENCES
    1. National Institute of Diabetes and Digestive and Kidney Diseases. Prostate enlargement: benign prostatic hyperplasia.
      NIH Publication No. 07-3012. June 2006.
    2. RAPAFLO® (silodosin) Capsules full Prescribing Information, Parsippany, NJ: Watson Pharma, Inc.; January 2013.
    3. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective α1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181:2634-2640.
    4. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474.
    5. Roehrborn CG, Kaplan SA, Lepor H, Volinn W. Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis. 2011;14:143-148.
    6. Shvartzman P, Borkan JM, Stoliar L, et al. Second-hand prostatism: effects of prostatic symptoms on spouses’ quality of life, daily routines and family relationships. Family Pract. 2001;18:610-613.
    7. Data on file, Watson Laboratories, Inc.
    8. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia:
      a 9-month, open-label extension study. Urology. 2009;74:1318-1322.
    9. Cunha, JP. Frequent urination. eMedicine Health from WebMD. Available at: http://www.emedicinehealth.com/frequent_urination/article_em.htm. Accessed April 22, 2013.
    10. Issa MM, Regan T. Medical therapy for benign prostatic hyperplasia—present and future impact. Am J Manag Care. 2007;13:S4-S9.
    11. Fenter TC, Naslund MJ, Shah MB, Eaddy MT, Black L. The cost of treating the 10 most prevalent diseases in men 50 years of age or older.
      Am J Manag Care. 2006;12(4 suppl):S90-S98.
    12. American Urological Association. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530-547.
    13. Medline Plus Medical Encyclopedia from NIH: Enlarged prostate. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/000381.htm. Accessed July 29, 2010.
    14. de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol. 1998;33:481-488.
    15. Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on α1-adrenoceptor antagonists. BJU Int. 2005;95(Suppl 4):29-36.
    16. Kobayashi K, Masumori N, Hisasue S, et al. Inhibition of seminal emission is the main cause of an ejaculation induced by a new highly selective α1A-blocker in normal volunteers. J Sex Med. 2008;5:2185-2190.
    17. Kaplan SA. Side effects of α-blocker use: retrograde ejaculation. Rev Urol. 2009;11(Suppl 1):S14-S18.
    18. JALYN (dutasteride and tamsulosin hydrochloride) Capsules full Prescribing Information, GlaxoSmithKline, October 2012.
    19. Rosen RC, Giuliano F, Cason CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47:824-837.
    20. Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol. 2003;5:72-80.
    21. Kaplan S, Roehrborn CG, Hill LA, Volinn W. Effect of estimated prostate volume on silodosin-mediated improvements in the signs and symptoms of BPH: does prostate size matter? Open Access J Urol. 2011;3:89-93.
    22. American Urological Association Foundation. Prostate Health Playbook. AUA Foundation. 2011. Available at: http://www.urologyhealth.org/_media/_pdf/KYS%20Playbook%2012-11.pdf. Accessed May 17, 2013.
    23. Ponholzer A, Madersbacher S. Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment.
      Int J Impot Res. 2007;19:544-550.
    24. Kuritzky L. A primary care physician’s perspective on benign prostatic hyperplasia. Rev Urol. 2003;5(suppl 5):S42-S48.
    25. Wolters R, Wensing M, Van Weel C, Van Der Wilt GJ, Grol RPTM. Lower urinary tract symptoms: social influence is more important than symptoms in seeking medical care. BJU Int. 2002;90:655-661.

RAPAFLO® is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

RAPAFLO® is not indicated for the treatment of hypertension.

Important Safety Information

RAPAFLO® is available only by prescription and is approved to treat male urinary symptoms due to BPH, also called an enlarged prostate. RAPAFLO® should not be used to treat high blood pressure. Only your doctor can tell if you have BPH, not a more serious condition like prostate cancer. RAPAFLO® should not be used in patients with severe liver or kidney disease as well as those taking certain antifungal or HIV drugs. Do not take RAPAFLO® if you know you are allergic to it or any of its ingredients. Avoid driving or hazardous tasks until you know how RAPAFLO® will affect you, as a sudden drop in blood pressure may occur, rarely resulting in fainting. If considering cataract surgery, tell your eye surgeon you're currently taking RAPAFLO® or have taken it in the past. Side effects include a decrease or absence of semen during sex, dizziness, diarrhea, lightheadedness upon standing or sitting up abruptly, headache, swelling of the throat and nasal passages, and stuffy nose.

To report suspected adverse reactions, contact Actavis, Inc. (formerly Watson Pharmaceuticals, Inc.) at 1-800-272-5525 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.